|
|
Volumn 2, Issue 9, 2011, Pages 484-486
|
|
ACS chemical neuroscience molecule spotlight on contrave
|
|
Author keywords
Bupropion; Contrave; Naltrexone; Obesity; Weight loss
|
|
Indexed keywords
AMFEBUTAMONE PLUS NALTREXONE;
HIGH DENSITY LIPOPROTEIN CHOLESTEROL;
TRIACYLGLYCEROL;
AMFEBUTAMONE;
ANTIOBESITY AGENT;
NALTREXONE;
BEHAVIOR MODIFICATION;
BLOOD PRESSURE;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR RISK;
COMORBIDITY;
DRUG EFFICACY;
DRUG INDICATION;
DRUG SAFETY;
DRUG TOLERABILITY;
DYSLIPIDEMIA;
GLYCEMIC CONTROL;
HEART DISEASE;
HEART RATE;
HUMAN;
HYPERTENSION;
NAUSEA AND VOMITING;
NEUROSCIENCE;
NON INSULIN DEPENDENT DIABETES MELLITUS;
OBESITY;
OUTCOME ASSESSMENT;
PHASE 3 CLINICAL TRIAL (TOPIC);
QUALITY OF LIFE;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
REVIEW;
RISK BENEFIT ANALYSIS;
SEIZURE;
SELF ESTEEM;
SELF REPORT;
WAIST CIRCUMFERENCE;
WEIGHT REDUCTION;
DOUBLE BLIND PROCEDURE;
DRUG APPROVAL;
DRUG EFFECT;
FOOD AND DRUG ADMINISTRATION;
UNITED STATES;
ANTI-OBESITY AGENTS;
BUPROPION;
CLINICAL TRIALS, PHASE III AS TOPIC;
DOUBLE-BLIND METHOD;
DRUG APPROVAL;
HUMANS;
NALTREXONE;
OBESITY;
OVERWEIGHT;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
WEIGHT LOSS;
|
|
EID: 84876024902
PISSN: None
EISSN: 19487193
Source Type: Journal
DOI: 10.1021/cn200076y Document Type: Review |
|
Times cited : (13)
|
|
References (10)
|
